Page 1214 - Basic _ Clinical Pharmacology ( PDFDrive )

1200 Index

Chlorophenothane (DDT), 1010t, durations of action of, 117t mechanism of action in, 108t, 110–112,
1010–1011, 1013f intermediate-acting, 122t 111f
Chlorophenoxy herbicides, 1013f, mechanism of action of, 117 mode of action of, 94f, 108f, 109
1013–1014 mode of action of, 94f, 108f, 109 organ system effects in, 112t, 112–115,
Chloroprocaine, 470, 472t. See also pharmacodynamics of, 117–118 113f
Anesthetics, local poisoning with cardiovascular system, 102f, 112t,
Chloroquine, 650, 918–921, 920t case study of, 107, 123 112–114, 113f
adverse effects of, 920–921 management of, 1041t, 1043–1044 CNS, 114
antimalarial action and resistance to, short-acting, 122t eye, 112
918–919 structure of, 115, 116f gastrointestinal tract, 114
chemistry and pharmacokinetics of, therapeutic uses of, 117t genitourinary tract, 114
918, 919f toxicity of, 120–121 neuromuscular junction, 108t, 111f,
clinical uses of Cholinesterase regenerators, 132–133, 115
amebic liver abscess, 920 135t, 136t PNS, 103f, 114
chemoprophylaxis, 919, 920t Choline transporter (CHT), 93, 94f respiratory system, 114
treatment, 919, 920t Cholinoceptor(s), 95, 98, 99t. See also secretory glands, 114
contraindications and cautions with, 921 Muscarinic (M) receptors; pharmacodynamics of, 108t, 110–115
malaria treated with, 918–921, 920t Nicotinic (N) receptor preparations available, 123t
Chlorothiazide, 264–265, 273t definition of, 98 Cholinomimetics, indirect-acting,
Chlorotrianisene, 723, 723f. See also subtypes and characteristics of, 107–108, 115–118, 122t
Estrogen(s) 108t chemistry and pharmacokinetics of,
Chlorphenesin, 488, 489t Cholinoceptor-blocking drugs, 124–134, 115–117, 116f, 117t
Chlorpheniramine, 282f, 283t, 296t. 135t mode of action of, 94f, 108f, 109
See also H 1 -receptor antagonists ganglion-blocking drug pharmacology pharmacodynamics of, 112t, 117–118,
Chlorpromazine, 511, 513f. See also in, 133–134 479f, 480f
Antipsychotic agents muscarinic receptor blockers, preparations available, 123t
description of, 160 124–129 Cholinoreceptor stimulants, 107. See also
psychosis treated with, 513f, 514–515, clinical pharmacology of, 130–133 Cholinomimetics
515t, 520t, 528t pharmacology of, 124–129 CHOP, for non-Hodgkin’s lymphoma, 970
Chlorpropamide, 758, 768t. See also preparations available, 136t Chorea, 492
Sulfonylureas subgroups of, 124 benign hereditary, 505
Chlorthalidone, 177, 264–265, 273t Cholinomimetics, 107–123. See also specific Huntington’s disease, 504f, 504–505,
Chlorzoxazone, 488 types 508t
Cholecalciferol, 789t. See also Vitamin D classification of, 107 Choriogonadotropin alfa, 674
Cholecystokinin (CCK), 92t clinical pharmacology of, 118–121, Christmas disease, 621, 622t
Cholesterol 122t, 123t Chronic kidney disease, 785–786
in cell membrane, 854 clinical uses in Chronic lymphocytic leukemia (CLL)
guidelines for, 629t antimuscarinic drug intoxication, description of, 970
Cholesterol 7α-hydroxylase, 631 119–120 immunization for, 1180t
Cholesteryl esters, 626 CNS, 120 Chronic myelogenous leukemia (CML),
Cholesteryl ester storage disease, 629t, 631 eye, 105f, 118 969–970
Cholestyramine GI and urinary tracts, 118–119 Chronic obstructive pulmonary disorder
description of, 636–637, 640t heart, 119 (COPD)
diarrhea treated with, 1100 neuromuscular junction, 111f, 119 asthma versus, 361
Choline acetyltransferase (ChAT), 93, 94f mode of action of, 94f, 108f, 109 exacerbations of, 361
Choline esters prokinetic activity of, 1097 muscarinic receptor blockers for,
description of, 109, 109f, 110t spectrum of action of, 90f, 103f, 126f, 130
direct-acting, 122t 107–108, 108f, 108t b 1 -selective blockers for, 164
Cholinergic fibers, 90f, 93 toxicity in treatment of, 360–361
Cholinergic junction, 93–95, 94f cholinesterase inhibitors, 120–121 Chronic pancreatitis, 400
Cholinergic nerves, 97–98 muscarinic stimulants, direct-acting, Chrousos syndrome, 710
Cholinergic poisoning, 132–133 120 Churg-Strauss syndrome, 357
Cholinergic transmission, 93–95, 94f nicotinic stimulants, direct-acting, Chylomicronemia, primary, 629t, 629–630
Cholinesterase inhibitors 120–121 Chylomicrons, 627
absorption, distribution, and metabolism Cholinomimetics, direct-acting, 109–115, Ciclesonide, 355
of, 115–117, 116f, 117t 122t Ciclopirox olamine, dermatologic topical,
Alzheimer’s disease treated with, 1063 chemistry and pharmacokinetics of, 109, 1072
chemical warfare use of, 121 109f, 110f, 110t Cidofovir, 868t, 869